Sign In
Buy QURE
$29.88
+3.12 (+11.66%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V.
08:23am, Tuesday, 03'rd Mar 2026
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
uniQure: The Worst Case Scenario Just Got Official (Rating Downgrade)
08:15am, Tuesday, 03'rd Mar 2026
uniQure faces a multi-year delay for AMT-130 after the FDA recommended a rigorous Phase 3 sham-controlled trial. AMT-130's risk-adjusted NPV drops over 70% due to lower Probability of Success and dela
Pre-Market Stock Futures: Futures are down big as oil shoots higher on Tuesday. After a big early morning sell-off on Monday, the buy-the-dip buyers returned with a vengeance, and by the end of the Mo
uniQure (NASDAQ:QURE) Sees Large Volume Increase After Better-Than-Expected Earnings
01:04am, Tuesday, 03'rd Mar 2026
Shares of uniQure N.V. (NASDAQ: QURE - Get Free Report) saw an uptick in trading volume on Monday following a stronger than expected earnings report. 7,361,027 shares changed hands during mid-day trad
New York, New York--(Newsfile Corp. - March 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
04:27pm, Monday, 02'nd Mar 2026
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
Block & Leviton announces a securities fraud lawsuit has been filed against uniQure (Nasdaq: $QURE). Investors who lost money should contact the firm.
uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face March 13, 2026, Deadline
11:45am, Monday, 02'nd Mar 2026
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In uniQure To Contact Him Directly To Discuss Their Options If you purchased or acquired
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
09:21am, Monday, 02'nd Mar 2026
uniQure (QURE) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to a loss of $1.5 per share a year ago.
FDA tells UniQure study data insufficient for brain disorder therapy application
07:22am, Monday, 02'nd Mar 2026
UniQure said on Monday the U.S. Food and Drug Administration has told the company that its data from an early-to-mid stage trial would not support a marketing application for its brain disorder gene t
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
07:05am, Monday, 02'nd Mar 2026
~ Held Type A meeting with FDA to discuss AMT-130 for Huntington's disease; Company evaluating Phase III development considerations and plans to request follow-up Type B meeting in the second quarter
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE
04:18am, Monday, 02'nd Mar 2026
LOS ANGELES, March 2, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against uniQure N.V. ("uniQure " or "the Company") (NASDAQ: QURE) for violations of §§10(b)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
03:18am, Monday, 02'nd Mar 2026
LOS ANGELES, March 2, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure" or "the Com
NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE)
05:45pm, Sunday, 01'st Mar 2026
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V.
